Glenmark Pharmaceuticals Limited has received final approval from the US Food and Drug Administration (US FDA) for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, the generic version of Chiesi USA, Inc.’s Cardene Capsules, 20 mg and 30 mg.
Glenmark Pharmaceuticals Inc., USA will distribute Glenmark’s Nicardipine Hydrochloride Capsules, 20 mg and 30 mg. The Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately $10.9 million, according to IQVIA sales data for the 12-month period ending October 2022, according to the statement.
Glenmark currently has 178 products approved for distribution in the US market and 46 ANDAs pending approval with the US FDA.